10X Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . 10X Genomics
TXG Stock  USD 19.66  0.56  2.93%   
10X Genomics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing 10X Genomics' valuation are provided below:
Gross Profit
444.4 M
Profit Margin
(0.07)
Market Capitalization
2.4 B
Enterprise Value Revenue
1.8185
Revenue
642.8 M
There are over one hundred nineteen available fundamental signals for 10X Genomics, which can be analyzed over time and compared to other ratios. Active traders should verify all of 10X Genomics prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself this quarter and beyond. The current Market Cap is estimated to decrease to about 1.7 B. Enterprise Value is estimated to decrease to about 1.5 B

10X Genomics Total Revenue

445.06 Million

Check 10X Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 10X Genomics' main balance sheet or income statement drivers, such as Tax Provision of 3.9 M, Net Interest Income of 21.1 M or Interest Income of 21.1 M, as well as many indicators such as Price To Sales Ratio of 3.01, Dividend Yield of 0.0 or PTB Ratio of 5.06. 10X financial statements analysis is a perfect complement when working with 10X Genomics Valuation or Volatility modules.
  
Build AI portfolio with 10X Stock
Check out the analysis of 10X Genomics Correlation against competitors.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

10X Genomics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets819.9 M1 B474 M
Slightly volatile
Short and Long Term Debt Total78.9 M157.7 M47 M
Slightly volatile
Other Current Liabilities71 M105.8 M42.9 M
Slightly volatile
Total Current Liabilities107 M153.5 M66.9 M
Slightly volatile
Other Liabilities5.3 M5.5 M12.6 M
Pretty Stable
Property Plant And Equipment Net210 M287.2 M116.3 M
Slightly volatile
Current Deferred Revenue25.1 M23.9 M7.2 M
Slightly volatile
Accounts Payable13.7 M12.7 M9.7 M
Slightly volatile
Cash389.3 M474 M230 M
Slightly volatile
Non Current Assets Total248.2 M356.9 M137.2 M
Slightly volatile
Non Currrent Assets Other2.8 M2.9 M7.5 M
Pretty Stable
Other Assets8 M8.5 M11.6 M
Pretty Stable
Long Term Debt18.9 M22.8 M13.9 M
Slightly volatile
Cash And Short Term Investments430.7 M523.4 M252.3 M
Slightly volatile
Net Receivables73.4 M82.5 M45.1 M
Slightly volatile
Common Stock Total Equity1.8 K2.3 K1.5 K
Slightly volatile
Common Stock Shares Outstanding96.7 M124.7 M57 M
Slightly volatile
Long Term Debt Total18.9 M22.8 M13.9 M
Slightly volatile
Liabilities And Stockholders Equity819.9 M1 B474 M
Slightly volatile
Non Current Liabilities Total100.9 M91.6 M141.1 M
Slightly volatile
Capital Surpluse2.2 B2.1 B813.1 M
Slightly volatile
Inventory50.5 M56.3 M29.3 M
Slightly volatile
Other Current Assets17.3 M22.2 M11 M
Slightly volatile
Other Stockholder Equity1.4 B2.3 B772.8 M
Slightly volatile
Total Liabilities178.7 M245 M206.2 M
Pretty Stable
Property Plant And Equipment Gross250.7 M440.6 M138.3 M
Slightly volatile
Short and Long Term Debt6.7 M11.4 M6.8 M
Slightly volatile
Total Current Assets571.6 M684.5 M336.8 M
Slightly volatile
Non Current Liabilities Other7.3 M7.7 M11.7 M
Slightly volatile
Net Working Capital464.7 M531 M269.9 M
Slightly volatile
Short Term Debt8.6 M11 M6.4 M
Slightly volatile
Common Stock2 K2.3 K1.5 K
Slightly volatile
Property Plant Equipment349.4 M332.7 M115.8 M
Slightly volatile
Capital Stock2.1 K2.3 K1.5 K
Slightly volatile

10X Genomics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision3.9 M3.6 M2.1 M
Slightly volatile
Interest Income21.1 M20 M5.4 M
Slightly volatile
Depreciation And Amortization25.1 M50.3 M17 M
Slightly volatile
Selling General Administrative245.2 M316.1 M151.6 M
Slightly volatile
Selling And Marketing Expenses2.7 M4.5 M1.7 M
Slightly volatile
Total Revenue445.1 M642.8 M269.6 M
Slightly volatile
Gross Profit328 M443.9 M202.1 M
Slightly volatile
Other Operating Expenses560.2 M753.7 M339.4 M
Slightly volatile
Research Development187.9 M238.6 M114.7 M
Slightly volatile
Cost Of Revenue117.1 M198.9 M67.6 M
Slightly volatile
Total Operating Expenses443.1 M554.8 M271.8 M
Slightly volatile
Reconciled Depreciation27.7 M43.8 M16.7 M
Slightly volatile
Income Tax Expense3.9 M3.6 M2.1 M
Slightly volatile

10X Genomics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation87.5 M109.1 M47.9 M
Slightly volatile
Begin Period Cash Flow348.5 M344.1 M205.4 M
Slightly volatile
Other Cashflows From Financing Activities6.5 M6.8 M21.9 M
Pretty Stable
Depreciation27.7 M43.8 M16.7 M
Slightly volatile
Other Non Cash Items1.6 M1.7 M19.4 M
Pretty Stable
Capital Expenditures5.6 M5.9 M25 M
Slightly volatile
Total Cash From Financing Activities6.5 M6.8 M73.1 M
Very volatile
End Period Cash Flow401.4 M474 M236.5 M
Slightly volatile
Change To Netincome111.7 M158.6 M68.7 M
Slightly volatile
Change To Liabilities11.1 M8.5 M7.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.013.165211.4595
Very volatile
Days Sales Outstanding67.8246.840264.8336
Slightly volatile
Stock Based Compensation To Revenue0.120.16970.0984
Slightly volatile
Capex To Depreciation0.130.13551.531
Pretty Stable
EV To Sales2.542.673310.8041
Very volatile
Inventory Turnover2.813.5312.4123
Pretty Stable
Days Of Inventory On Hand132103164
Very volatile
Payables Turnover16.4115.62416.2513
Slightly volatile
Sales General And Administrative To Revenue0.640.55560.6181
Slightly volatile
Research And Ddevelopement To Revenue0.330.37120.4243
Slightly volatile
Capex To Revenue0.00880.00920.0795
Pretty Stable
Cash Per Share5.654.19574.7557
Pretty Stable
Days Payables Outstanding22.1923.3613116
Slightly volatile
Intangibles To Total Assets0.06740.06420.0367
Pretty Stable
Net Debt To EBITDA2.712.85194.271
Pretty Stable
Current Ratio4.114.46034.2307
Slightly volatile
Receivables Turnover4.857.79255.69
Slightly volatile
Capex Per Share0.04520.04760.4271
Very volatile
Revenue Per Share6.25.15295.8785
Slightly volatile
Interest Debt Per Share1.121.26441.0117
Very volatile
Debt To Assets0.120.15150.1239
Slightly volatile
Operating Cycle249150232
Very volatile
Days Of Payables Outstanding22.1923.3613116
Slightly volatile
Ebt Per Ebit0.340.35991.2374
Very volatile
Quick Ratio3.784.09313.8978
Slightly volatile
Net Income Per E B T0.821.09111.0062
Very volatile
Cash Ratio3.963.08873.0264
Slightly volatile
Cash Conversion Cycle125127110
Slightly volatile
Days Of Inventory Outstanding132103164
Very volatile
Days Of Sales Outstanding67.8246.840264.8336
Slightly volatile
Fixed Asset Turnover2.132.23856.7353
Slightly volatile
Debt Ratio0.120.15150.1239
Slightly volatile
Price Sales Ratio3.013.165211.4595
Very volatile
Asset Turnover0.70.61730.7666
Slightly volatile
Gross Profit Margin0.840.69050.8034
Slightly volatile

10X Genomics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.8 B3.3 B
Slightly volatile
Enterprise Value1.5 B1.5 B3.1 B
Slightly volatile

10X Fundamental Market Drivers

Forward Price Earnings196.0784
Cash And Short Term Investments523.4 M

10X Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About 10X Genomics Financial Statements

10X Genomics stakeholders use historical fundamental indicators, such as 10X Genomics' revenue or net income, to determine how well the company is positioned to perform in the future. Although 10X Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in 10X Genomics' assets and liabilities are reflected in the revenues and expenses on 10X Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in 10X Genomics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue23.9 M25.1 M
Total Revenue642.8 M445.1 M
Cost Of Revenue198.9 M117.1 M
Stock Based Compensation To Revenue 0.17  0.12 
Sales General And Administrative To Revenue 0.56  0.64 
Research And Ddevelopement To Revenue 0.37  0.33 
Capex To Revenue 0.01  0.01 
Revenue Per Share 5.15  6.20 
Ebit Per Revenue(0.17)(0.18)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:
How To Invest In 10X
Details
Is 10X Stock a good investment?
Details
What is 10X Genomics' Net Worth?
Details
Largest Life Sciences Tools & Services Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of 10X Genomics Correlation against competitors.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Can Life Sciences Tools & Services industry sustain growth momentum? Does 10X have expansion opportunities? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating 10X Genomics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(0.35)
Revenue Per Share
5.153
Quarterly Revenue Growth
0.006
Return On Assets
(0.06)
Return On Equity
(0.06)
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, 10X Genomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY